A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3

NCT00000754 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Interferon alfa-2a
DRUG: Zidovudine
DRUG: Zalcitabine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]
[object Object]